Souhaitez-vous accéder aux communiqués récents ?

Kensington, MD, USA and Munich/Martinsried, Germany, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics...

"Our cells naturally become more mesenchymal over time, so PRP’s ability to potentially reverse this trend is of tremendous scientific interest"

PolarityBio thanks the clinical trial sites and, most importantly, the participants, for making this milestone in DFU biologic therapy development possibleFinal trial results anticipated in the first...

6-month GLP-tox study reinforces favorable safety profile of Tiprelestat Phase II Study in Pulmonary Arterial Hypertension (PAH) to be initiated by Stanford University in mid-2026 Kiel, GERMANY,...

Longeveron presents new MRI biomarker data linking neuroinflammation to clinical outcomes in patients with mild Alzheimer's disease at CTAD 2025.

New advisory board brings further world-class expertise in oncology, neurology, geographic market expansion, and AI enabled clinical trial delivery to support biotech innovators LETCHWORTH GARDEN...

December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical...

MUTTENZ, Switzerland, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company pioneering innovation in peritoneal dialysis (PD), is pleased to announce the...

The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026 Clinical Trial Application (CTA) submission marks the advancement of Tangram’s GalOmic RNAi...

Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621...